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Biomarkers have been playing an increasingly significant role in clinical decision 
making processes worldwide. Numerous studies are being undertaken across the 
globe in the elusive search for the ideal biomarker for each clinical condition. In the 
emergency department, where rapid diagnosis of various diseases like acute coro-
nary syndromes, pulmonary embolism, heart failure, sepsis, acute renal failure etc. 
is of utmost importance, specific biomarkers can expedite the time to diagnosis and 
treatment. To enumerate, the following biomarkers have proved their worth within 
the setting of emergency departments across the world. The role of cardiac tropo-
nins and CK-MB has been well established in the clinical algorithms to detect myo-
cardial infarction. Newer markers like Heart Fatty Acid Binding Protein (H-FABP), 
BNP, Pro BNP as well as Ischemia modified albumin (IMA) are coming into the fray 
in the detection of cardiovascular emergencies, especially in the detection of heart 
failure. Novel biomarkers like Mid-region Proadrenomedullin (MR-proADM) are 
found to be useful in sepsis along with Tumour necrosis factor-alpha (TNF-alpha), 
Interleukins and Presepsin in burns patients. Human neutrophil gelatinase-associ-
ated lipocalin (NGAL) levels can detect renal failure much earlier than conventional 
methods. S100 calcium binding protein B (S100B) has been found to be useful in 
detection of CNS injury and hence can be used to avoid unnecessary radiation to 
patients in the form of CT scans. Point of care testing of many of these biomarkers 
in the Emergency department itself paves way for a revolutionary step in faster 
emergency care delivery and better patient outcomes.
Keywords: biomarker, emergency medicine, troponin, sepsis, burns, acute kidney 
injury, head injury
1. Introduction
According to the National Institute of Health (NIH) Biomarkers Working 
Group, a biological marker (biomarker) is defined as “a characteristic that is 
objectively measured and evaluated as an indicator of normal biological pro-
cesses, pathogenic processes, or pharmacologic responses to a therapeutic inter-
vention” [1].
Worldwide, biomarkers have been primarily studied specifically in the setting 
of diseases. Even so, it is imperative to understand the concept that a biomarker in 
the human milieu can be present as a result of normal physiological functioning 
and need not be the result of a pathological process always. Analysis of various 
biomarkers, both quantitatively and qualitatively have resulted in better understand-
ing of physiological as well as pathological processes of the human body. An ideal 
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biomarker should aid in early diagnosis, help in risk stratification, be able to moni-
tor response to treatment modalities and predict outcomes better than the clinical 
processes and investigations existing in medical practice at that point of time [2].
In medical practice, biomarkers can be of diagnostic or prognostic value. In the 
setting of practicing Emergency medicine, diagnostic biomarkers assume greater 
significance. In the Emergency department, where time is of the essence, diagnostic 
biomarkers help in quick clinical decision making as well as patient disposition. A 
biomarker that is able to make a clinical differentiation between two similar disease 
conditions is highly valuable for an emergency physician. This helps in rapid diagnosis, 
which leads to faster treatment initiation. Faster the treatment can be initiated, faster 
the patient movement. A faster TAT (turnaround time) for patients in the ED trans-
lates to lesser waiting times in the ED. An ideal biomarker in the Emergency depart-
ment should have the following characteristics—High diagnostic accuracy which 
involves a high degree of sensitivity with reasonable specificity, should be reproducible 
across platforms and should be cost effective to the patient and the clinician.
Numerous biomarkers have been extensively studied for the purpose of clinical 
utility, but only a few handfuls have proved their mettle in clinical practice. The 
abundance of biomarker tests available, pose a not so friendly dilemma to the clini-
cian of the present. Understandably, there is still a long way to traverse from the 
laboratory table to the patient bedside. Numerous trials and research activities are 
underway across the world in the field of biomarkers. Most of them are still in various 
phases of preclinical trials and are expected to be available by the patient’s bedside in 
a few years’ time.
In modern clinical practice, biomarkers are being used more and more for clinical 
decision making. The current gamut of biomarkers available in the clinical realm 
have changed the way we practice medicine. The increase in the use of biomarkers 
for clinical decision making has expedited the patient disposition to a great extent. 
Having said that, there is also the other side of the coin which is the increase in the 
health care cost. The over dependence of clinicians on biomarkers should be viewed 
with caution as this escalates the overall cost of treatment and the patients will have 
to bear that burden. The decision to make use of biomarkers in the clinical context 
should be individualised and targeted to prevent its overuse or abuse [3]. This will 
put a strain on the already scarce resources in the health care sector. It is always 
pertinent to remember that—A biomarker should always be evaluated in the clinical 
context and should never be used as a standalone tool for clinical decision making.
In Emergency medical practice, majority of the biomarker work has been 
focussed in the field of cardiology, renal failure and sepsis, as early detection and 
prompt interventions in the early phases of the diseases can significantly alter the 
natural course of the disease and improve the patient morbidity and mortality. 
Other areas of focus are hepatic diseases, traumatic brain injury, venous throm-
boembolism etc., where biomarkers are increasingly being tested for their clinical 
utility. Therefore, the chapter focuses in detail on these clinically significant 
biomarkers.
2. Acute coronary syndromes
Acute coronary syndromes have been in the forefront of novel biomarker evalu-
ation research due to its widespread prevalence as well as the need for detection in a 
time sensitive manner. Almost 20 million patients with symptoms of acute coronary 
syndromes present to emergency departments in North America and Europe 
annually [4, 5]. Numerous studies have been performed on various biomarkers, 
the conventional markers as well as high sensitive variants, and also with respect to 
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different time frames. In the Emergency department, making a rapid diagnosis of 
acute myocardial infarction is of utmost importance, as ‘time is muscle’. The earlier 
a diagnosis of ACS can be made, the earlier revascularisation can be initiated. Early 
treatment can decrease the morbidity and mortality to a significant extent in case 
of ACS. At the same time, it is also important to make sure deserving patients are 
disposed of from the ED as soon as possible in a time dependent manner once ACS 
is ruled out. This assumes more significance in EDs that receive a high volume of 
patients and need patients to be either admitted for further workup or discharged 
in a timely manner. At the same time, discharging patients from the ED always has 
a risk of patients ending up in an adverse cardiac event. Institutional protocols that 
include serial biomarker evaluation help in minimising these risks to a great extent.
Historically, biomarkers like LDH (lactate dehydrogenase) and AST (aspartate 
aminotransferase) were tried in the detection of an acute coronary syndrome 
especially towards the end of 20th century. Their clinical significance slowly began 
to decline with the advent of better alternatives as well as lack of specificity. The 
next in line were the markers with better specificity and sensitivity, namely—the 
troponins and creatine kinase. As the 21st century is taking its foothold, the scien-
tific community is focussing its attention on these biomarkers for detection of acute 
coronary events, a leading cause of death worldwide. The research was primarily 
focussed on Creatine Kinase – MB fraction, which used to be the gold standard of 
evaluation of ACS. But, that has given way to the newer biomarkers—Troponin I 
and Troponin T – both conventional and high sensitive, which are being studied 
extensively across the globe.
2.1 Creatine kinase: MB
Creatine Kinase is an intracellular enzyme with a dimeric molecule which has 
3 isoforms—CK-MM (muscle), CK-BB (brain) and CK-MB (myocardium), based 
on the organ of origin. CK-MB is the isoenzyme fraction which is predominantly 
seen in cardiac muscle and hence the utility in detecting cardiac muscle damage. 
This marker is leaked into the systemic circulation from the cellular cytosol due to 
disruption of the cell membrane as a result of myocardial injury. This marker can 
be assayed by a clinician to help in the diagnosis of myocardial infarction. CK-MB 
isoenzyme can be detected in the bloodstream about 4–6 hours after the onset of 
chest pain. It peaks by 12–24 hrs and returns to baseline by 12–48 hours. This short 
time window of rise and fall of CK MB is especially useful in detecting reinfarc-
tion or infarct extension in a patient in whom the troponin values might be already 
elevated as a result of an infarct. It is also helpful in identifying complications in 
patients who have undergone revascularization procedures in the cardiac care unit. 
The reference values for CK-MB are as follows—males: ≤ 7.7 ng/mL and females: 
≤ 4.3 ng/mL. CK MB assay should always be viewed with a pinch of salt since it 
is a subunit of the total CK in the system. Abnormal elevations of CK MB can be 
detected along with an increased level of total CK in cases of traumatic muscle 
injuries, rhabdomyolysis, myopathies etc. It is worthwhile to note that the normally 
CK-MB fraction accounts for only 3–5% of the total CK in the body and any increase 
beyond 30–50% of the total CK should prompt suspicion of abnormal beta subunit 
synthesis. But, over the past few years, the burden of diagnosis of acute myocardial 
injury has been shifted on to the shoulders of troponins [6].
2.2 Cardiac troponins
Troponin is a complex protein molecule comprising of three regulatory proteins 
playing an integral role in the contraction of cardiac and skeletal muscle. These 
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three subunits are namely—Troponin I (TnI), Troponin T (TnT) and Troponin 
C (TnC). Each subunit has a unique function. Troponin T binds to the troponin 
components of Tropomyosin, troponin I inhibits the interaction of myosin with 
actin and troponin C has the sites for binding of calcium ions to initiate muscle 
contraction.
Similar to creatine kinase, any cellular injury leads to leakage of the troponins 
into the systemic circulation thereby providing a window for diagnosis of acute 
myocardial infarction. Troponins have much higher specificity and sensitivity 
than creatine kinase. The utility of cardiac troponins especially – Troponin T and 
Troponin I has been validated in various studies across the world and hence has 
been incorporated into the diagnostic guidelines of acute myocardial infarction.
Normally troponins are not detectable in the bloodstream due to the minute quan-
tities in open circulation, which is <0.01 ng/mL for Troponin T and ≤ 0.04 ng/mL for 
Troponin I. After a myocardial injury, elevated troponin levels in the bloodstream can 
be detected within a period of 4–6 hours, by conventional methods. The reason for this 
delay in detection has been attributed to the molecular weight and size (21–37 kDa). 
This can cause clinically significant delay in the diagnosis of myocardial infarction 
especially in the setting of nonspecific ECG changes. This has led to the advent of high 
sensitive assays which can detect troponins at much lower levels (at the levels of ng/L) 
and that too, much earlier than conventional methods. Troponins can be detected as 
early as 2 hours after the ischemic event by high sensitive troponin assays currently in 
clinical practice. This also has a caveat, that is, troponin levels can be detected in the 
circulation even without myocardial injury [4, 5]. Hence a troponin value above the 
99th percentile is taken as a diagnostic cut-off for detection of myocardial ischemia. A 
20% rise or fall from the baseline within a period of 3–6 hours can confirm the diag-
nosis of an acute myocardial infarction according to the National Academy of Clinical 
Biochemistry [6]. It has been recommended by the American college of Cardiology 
(ACC) that serial values of troponin be considered at 6–9 hr. intervals to rule out 
NSTEMI [7]. European Society of Cardiology has also reiterated the importance of 
doing serial assessments of troponins rather than making a clinical decision based on 
a single value [8]. In a recent large multicentre evaluation in patients with suspected 
ACS who presented within 8 hours of symptom onset, it was found that it was possible 
to diagnose ACS with 3-hour marker samples rather than the conventional method of 
doing serial markers at 6 hour intervals, without losing out on the diagnostic accuracy 
[9]. Along with clinical evidence of MI, an elevation of troponin level more than 5 
times the upper limit compared to the baseline is needed to diagnose a PCI-related MI 
and more than 10 times the upper limit to diagnose a CABG-related MI [10]. Multiple 
studies have shown that there is correlation between the levels of troponins and 
development of adverse cardiac events [11, 12].
Elevated troponin levels may not always indicate myocardial injury [13, 14]. 
It can also be elevated in non-ischemic conditions as well. A rise/fall in troponin 
levels are needed to detect acute MI in patients in whom troponins will be elevated 
otherwise, like renal failure. Even though sensitivity is increased, specificity has 
come down which may indicate an underlying disease than an acute coronary event. 
Various causes of nonischemic elevation of troponins are detailed in the below table 
(Table 1). The troponin levels have to be interpreted only in the appropriate clinical 
setting, failing which the physician may be misled to an alternate diagnosis [15].
2.3 Other contenders
Numerous other biomarkers have piqued the interest of the scientific com-
munity to identify acute coronary events more early as well as more precisely. Very 
few have actually stood on their own when compared to troponin studies. The most 
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common drawback being the cost of the investigation as well as availability. Some of 
the examples are discussed below.
Myoglobin (Mb) peaks within minutes of cardiac ischemia. With the recent 
advancements for detection of hs-troponin levels, the utility of Mb has come 
down in the diagnostic algorithm [16]. A few examples of other novel bio-
markers of myocardial ischemia/injury that have undergone clinical trials are 
given below in Table 2. They include cardiac intracellular proteins, markers of 
neurohormonal activation, markers for haemostatic activity, vascular inflam-
mation markers etc. [17]. In this study, the assessment of H-FABP within the 
first 4 h of symptoms was found to be superior to cTnT for detection of MI. But 
the reduced specificity of H-FABP is presently limiting its usefulness in clinical 
practice. Soluble CD40 ligand and choline which are biomarkers signalling the 
instability of atherosclerotic plaque formation, have been studied, but did not 
show add any prognostic or diagnostic value to the existing ones in practice. 
But the other biomarkers they studied along with this, did not show any favour-
able clinical significance.
3. Cardiac failure
Cardiac failure is a complex process involving a multitude of pathophysiological 
processes. As a result of this, various biomarkers have been identified which cor-
relate with specific aspects of heart failure. The marker which has made its mark in a 
clinically significant manner are the natriuretic peptides-B type natriuretic peptide 
(BNP) and NT pro BNP.
Cardiac Non Cardiac
• Congestive cardiac failure • Pulmonary Embolism
• Myocarditis • Renal failure
• Pericarditis • Sepsis
• Infiltrative diseases • Stroke
• Blunt chest trauma
Table 1. 
Examples of non ACS-causes of elevated troponin levels:
• Myoglobin (Mb) P
• Heart Fatty Acid Binding Protein (H-FABP)
• Glycogen Phosphorylase-BB (GP-BB)
• NT-Pro-Brain Natriuretic Peptide (NT-ProBNP)
• D-Dimer
• High Sensitivity C-Reactive Protein (HsCRP)
• Myeloperoxidase (MPO)
• Matrix Metalloproteinase-9 (MMP-9)
• Pregnancy Associated Plasma Protein-A (PAPP-A)
• Soluble CD40 Ligand (SCD40L)
Table 2. 
Newer biomarkers for cardiac ischemia.
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3.1 B type natriuretic peptide (BNP) & NT pro BNP
BNP is secreted from the ventricles as a result of neurohormonal activation due 
to volume overload and resultant stretching of the myocardial muscle fibres. In 
patients with left ventricular dysfunction/failure, high plasma levels of BNP and NT 
pro BNP are specific for elevated filling pressures in the cardiac chambers. This can 
be used in the clinical context for the diagnosis as well as prognostication of cardiac 
failure. ProBNP is a 108-amino acid polypeptide precursor which is stored in secre-
tory granules in both ventricles and, to a lesser extent, in the atria. After proBNP 
is secreted, it is cleaved to the 76-peptide, biologically inert N-terminal fragment 
NT-proBNP and the 32-peptide, biologically active hormone BNP. BNP is rapidly 
cleared from the circulation; the plasma half-life being approximately 20 min. No 
receptor-mediated clearance of NT-proBNP is known to occur, because of which 
NT-proBNP has a prolonged half-life of 60–120 min. The reference values for 
NT-proBNP varies widely with age and gender, which can be tricky for the clinician 
while assessing patients, especially in the elderly population (Table 3).
In the multicentre Breathing Not Properly Study [18], using plasma BNP level of 
100 pg/mL as cut off, gave a sensitivity of 90%, specificity of 76% and a diagnostic 
accuracy of 81% which was superior to clinical assessment alone in a series of 1586 
patients who presented to the ED with acute dyspnoea. A BNP level < 100 pg/ml or an 
NT-proBNP level < 300 pg/ml can essentially rule out Acute HF in most cases. When 
using N-terminal proBNP for the diagnosis of acute CHF, a value of 900 pg/mL has 
high specificity and sensitivity.
Apart from left ventricular failure, these biomarkers can be elevated in numer-
ous other conditions which can cause myocardial stretch. Patients with right 
ventricular failure secondary to pulmonary embolism or pulmonary hypertension, 
valvular heart disease, arrhythmias such as atrial fibrillation, renal failure and 
advanced age may also have elevated levels of BNP or NT-proBNP [19]. In severe 
renal failure, the NT-pro BNP value of >1200 pg/mL is needed to make a diagnosis 
of cardiac failure. A common clinical scenario in which the patient is obese, the 
pro-BNP values can be falsely lower which can mask cardiac failure and lead to 
misdiagnosis.
The European Society of Cardiology Task Force has recommended that the 
algorithm for HF diagnosis should include an NP assay as the first step along with 
electrocardiography (ECG) and chest X-ray [20]. Biomarkers are not just useful in 
the diagnostic algorithm, but also in guiding treatment. In a meta-analysis [21] of 
2686 patients in 12 randomised trials, the researchers found that the use of cardiac 
peptides to guide pharmacologic therapy significantly reduces mortality and HF 
related hospitalisation in patients with chronic HF.
As discussed in the previous section, Troponin I (TnI) also plays an important 
role in the pathophysiological profile of cardiac failure. Newer markers that 
have potential to be significance in the future for diagnosis and prognosis in 






Reference values for NT-ProBNP:
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myeloperoxidase (MPO), soluble toll-like receptor-2 (ST2) and soluble fms-like 
tyrosine kinase receptor-1 (sFlt-1). Recently, a study in which the amount of 
exhaled acetone is measured has shown promise as a newer non-invasive modal-
ity for cardiac failure assessment [22]. A recent study attempted to evaluate the 
predictive utility of these biomarkers with a multimarker score which included 
BNP, troponin I and creatinine apart from the above markers. They concluded 
that a multimarker score significantly improves prediction of adverse events in 
ambulatory patients with chronic heart failure [23]. But, NACB’s practice guide-
lines on cardiac biomarker testing specifically recommends against routine use of 
biomarker testing only for risk stratification [24]. The newer entries into this field 
include galectin-3 [25], MR-proANP (midregion pro–atrial natriuretic peptide) 
[26], MR-proADM (mid regional pro-adrenomedullin), co-peptin, adiponectin, 
pentraxin-3, soluble ICAM-1(intercellular adhesion molecule-1), PAPP-A (preg-
nancy associated plasma protein A) etc.
4. Pulmonary embolism
In a case of suspected pulmonary embolism, laboratory evaluation by biomarker 
levels is primarily helpful in ruling out the diagnosis in low probability scenarios, 
rather than ruling in a confirmation of a diagnosis. D-dimer has been in clinical use 
extensively since the past few decades and the other markers which are increasingly 
used are troponins, BNP and Ischemia modified albumin (IMA).
4.1 D-dimer
D-dimer is a degradation product produced by plasmin during fibrinolysis. The 
reference value of D-dimer is ≤500 ng/mL Fibrinogen equivalent Units (FEU). It has 
very low specificity, but a high sensitivity. Due to the low specificity, a clinical diag-
nosis of pulmonary embolism requires a strong clinical suspicion. In order to help the 
clinician in this regard, various scoring systems to assess the probability of making a 
diagnosis of PE have been devised. Well’s criteria and its modified version are among 
the most commonly used. These scoring systems assist the clinician in assessing the 
probability of a diagnosis of PE along with the blood levels of the biomarker used. In 
patients with a low pretest probability of PE as assessed by well’s criteria and a nega-
tive d-dimer value, the diagnosis of pulmonary embolism can be essentially ruled out 
without any probability of adverse events happening later [27, 28].
4.2 Ischemia modified albumin (IMA)
Ischemia modified albumin (IMA) is a newer marker that has shown potential 
as a substitute for D-dimer as it has been found to be better than the latter in a 
few studies due to its better positive predictive value [29]. The reference value for 
IMA is ≤0.540 ABSU. In patients with pulmonary embolism, more so in those who 
develop RV dysfunction, other biomarkers like troponins and BNP are also found 
to be elevated. This occurs due to the increased pulmonary vascular resistance, 
pulmonary artery pressure and resultant RV afterload. The elevated troponin 
levels can pose a dilemma for a clinician who wants to rule out ACS as well in the 
clinical setting as the symptoms of both the conditions may overlap significantly. 
The elevated levels of BNP/NT pro-BNP in patients with pulmonary embolism 
have been found to be associated with increase in risk for complications and 30-day 
mortality [30].
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5. Sepsis
Sepsis is a complex process that stems from a combination of features of a 
systemic inflammatory response to a known or presumed infection. It is associated 
with a very high mortality rate around 30% not to mention the significant economic 
impact on the healthcare system [31]. Sepsis can be viewed as a chain of events in 
the body as a response to an inciting agent through an inflammatory pathway. This 
provides clinicians the opportunity to diagnose sepsis early by either picking up the 
inciting agent or the inflammatory response to the agent. More than 170 biomarkers 
have been identified as useful for evaluating sepsis [32], which itself points to the 
fact that none of them can be used as a single marker for accurate diagnosis or prog-
nosis. C-reactive protein, procalcitonin and serum lactate are among the prominent 
ones used extensively worldwide at present.
5.1 C-reactive protein
C-Reactive protein, one of the most commonly used markers for sepsis, is 
synthesised in the liver as an acute phase reactant. The normal levels in a healthy 
adult individual tends to be below 10 mg/L. Depending on the severity, any stress 
or stimulus can cause an elevation in the CRP levels, even manifold up to 500 mg/L. 
The levels peak around 36–48 hrs and the plasma half-life is approx. 19 hrs. 
Although very commonly used as an inflammatory marker, it lacks specificity as it 
is found to be elevated in numerous conditions like post-operative patients, burns, 
myocardial infarction and inflammatory/rheumatic diseases as well [33]. It can 
be elevated even in normal individuals especially in elderly as well as pregnancy. 
Moreover, even a viral infection can cause a mild increase in the serum levels of 
CRP, contrary to popular belief. The sensitivity and specificity of CRP as a marker 
for bacterial infections are 68–92% and 40–67%, respectively [34, 35]. CRP plasma 
levels have shown to correlate with the severity of infection [36] which makes it a 
useful marker to assess the response to pharmacological treatment.
5.2 Procalcitonin (PCT)
It is a 116-amino acid polypeptide which is the prohormone of calcitonin. It has a 
short half-life (25–30 hours), and is encoded by the CALC-1 gene. PCT is normally 
produced by neuroendocrine cells, mainly in the thyroid (C-cells), from which 
calcitonin is derived which is responsible for regulation of calcium metabolism in 
the body. It is also produced in low amounts in other neuroendocrine cells in the 
intestine and lungs. The CALC-1 gene is normally suppressed in non-endocrine 
tissues. Bacterial infection stimulates CALC-1gene transcription in non-endocrine 
cells [37], leading to increased PCT production which can be detected in the 
circulation making it a marker for diagnosis of bacterial infection and sepsis. PCT is 
released from various organs including lung, liver, kidney, pancreas, spleen, colon, 
and even adipose tissues in infectious conditions. In healthy individuals, the serum 
PCT levels are <0.1 ng/ml, which increases in response to an infective stimulus. 
Serum PCT levels begin to rise around 4 hrs after the insult and peaks by 24 hrs. The 
half-life of PCT is approx. 24 hrs and after the infectious process has started resolv-
ing, PCT levels decrease by almost 50% every day [38]. In a systematic review and 
meta-analysis, PCT with a cut-off median value of 1.1 ng/mL was found to be more 
specific (specificity - 81%) than CRP (67%) for differentiating bacterial infection 
among hospitalised patients [39]. PCT also has a sensitivity of 77% which makes it a 
useful marker for early diagnosis of sepsis [40]. These features make PCT a favour-
able biomarker to be used for guidance of antibiotic stewardship as well to reduce 
the ever increasing inappropriate use/abuse of antibiotics [41].
9
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5.3 Serum lactate
Lactate is produced in the body even normally, which gets cleared off rapidly in 
healthy individuals. But, in cases of sepsis and resultant hypoperfusion, the levels 
of lactic acid increase when anaerobic metabolism increases in the body. Lactate 
clearance has been shown in a prominent light in the ‘Early goal directed therapy’ 
of septic patients. This indicates that, more than a diagnostic marker, lactate has 
prognostic significance in patients with sepsis. Recent studies have shown that 
patients with even a milder increase in serum levels in the range of 2–4 mmol/L 
were at an increased risk of morbidity and mortality [42]. In a study conducted in 
an urban academic centre which included 1278 patients with infections, those with 
lactate levels above 4 mmol/L had higher in-hospital mortality rates than patients 
with lactate levels less than 2.5 mmol/L (28.4% vs. 4.9%) [43]. The bottom line is, 
the better the lactate clearance, better the outcome of the patient [44].
5.4 Proadrenomedullin (MR-proADM)
Adrenomedullin (ADM) is a 52-amino acid ringed peptide produced from endo-
thelial cells in cardiovascular, renal, pulmonary, cerebrovascular and endocrine 
tissues. It is a potent endogenous vasodilator in the human body. ADM is not easily 
measurable due to its very short half-life of 22 minutes in the circulation, its rapid 
degradation by proteases, and the formation of complexes with circulating comple-
ment factor H [45]. The prohormone of ADM - ProADM can be used as a surrogate 
marker for this purpose as it is more easily quantifiable, and the tools required for 
this are available commercially. The mid-regional fragment of proadrenomedullin 
(MR-proADM) is a marker of endothelial dysfunction/inflammation and therefore 
can be seen in elevated levels in numerous disease conditions. Pro-ADM has been 
found to be an independent predictor for adverse outcomes in patients with COPD 
[46]. It has also been studied in the context of burns, in which it was found to have 
utility in early recognition of onset of sepsis in burns victims [47]. It is still early 
days for MR-proADM in routine clinical practice as many studies [48] have failed 
to demonstrate any added utility with respect to other less expensive parameters 
presently available. For healthy individuals, the reference values for MR pro ADM is 
<0.5 nmol/L.
5.5 Other markers of sepsis
Cytokines like TNF, IL-1β and IL-6 are the predominant inflammatory media-
tors responsible for the initial inflammatory response and the levels correlate with 
the organ damage and mortality [49]. Similarly, High-mobility group box 1 protein 
(HMGB1) and Macrophage migration inhibitory factor (MIF) are also found to 
increase in patients with severe sepsis and septic shock and is correlated with the 
degree of organ failure [50, 51]. Lipopolysaccharide-binding protein (LBS) is an 
acute phase protein which increases in sepsis and makes it useful as a diagnostic 
tool as well as a marker for severity of the disease [52, 53]. Other biomarkers like 
serum amyloid A, eosinophil count, mannan and antimannan, and IFN-γ-inducible 
protein 10 also show potential to be of use in the future.
6. Burns
In patients who are hospitalised with burns, sepsis is considered as one of the 
most important causes for mortality. Biomarkers which can help pick up the onset 
of sepsis in burn patients in the early phase itself will be useful in the proactive 
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management of complications. Procalcitonin, Tumour necrosis factor-alpha 
(TNF-alpha), MR Pro-ADM, Interleukins 6, 8 & 10, Presepsin are among the major 
ones studied in this context in addition to assessment of single-nucleotide polymor-
phisms (SNPs) and leukocyte transcriptomes [54].
6.1 Procalcitonin
PCT has been extensively studied in the context of sepsis, but literature regard-
ing studies in burns are much lesser in comparison to other critical conditions. 
Serum levels of PCT were found to be elevated in patients who developed infections 
after burns in one of the initial studies done in 1993 which had 9 burns patients 
included among the 79 general patients enrolled in the study [55]. In a recent meta-
analysis of around 12 studies in burns patients led the investigators to believe that 
PCT has a strong ability to differentiate between patients with sepsis and without 
sepsis [56]. The study proposed that a PCT value >1.47 ng/mL can prompt the clini-
cians to initiate early antibiotic therapy to counter the development of sepsis and 
improve patient outcomes.
6.2 Tumour necrosis factor-alpha (TNF-alpha)
It is a proinflammatory cytokine and has been researched worldwide in vari-
ous disease conditions among the host of numerous inflammatory mediators. It 
is produced ubiquitously in the body in response to various stimuli which can be 
infectious or ischemic in nature. They include endotoxins, complement system 
activation, hypoxia, ischemia as well as reperfusion [57]. TNF-alpha has been found 
to be elevated in burns and the values are seen to be higher in patients found to be 
in sepsis [58]. It has also been shown to have a prognostic value in burns victims. In 
burns patients who were treated with GM-CSF, the values of TNF alpha were shown 
to come down gradually as the treatment progressed [59], hence proving its role as a 
prognostic indicator. Reference value: ≤ 2.8 pg/mL.
6.3 Interleukins
The interleukins (ILs) are a large class of cytokines that promote cell-to-cell 
interactions and the stimulation of humoral or cell-mediated immune responses. 
They were initially thought to be produced only by the leukocytes, but have been 
found to be produced from numerous sources since then. The IL family consists of 
a huge number of members of which IL-6, IL-8 and IL-10 have been shown to be 
associated with evaluation of sepsis in burns patients. IL-6 has been found to be 
elevated in burns patients with sepsis [60]. It not only helps in the early diagnosis, 
but also has prognostic significance regarding the mortality as the levels have been 
found to be correlating with the size of the burns [61]. Recently, a meta-analysis of 
studies done on critically ill patients regarding markers of sepsis found IL-6 to have 
a high specificity, hence making it a suitable marker to confirm an infectious pro-
cess [62]. Similarly, studies have found that IL-8 levels in burns patients correlate 
with the development of sepsis and multi-organ failure resulting in mortality [63]. 
The authors of the study opined that it can be used as a biomarker for monitoring 
the morbidity and mortality of burn patients developing sepsis. IL-10, similar to 
its counterparts, have been shown to have a correlation to development of sepsis 
in burn patients. Normally, the serum levels increase after the injury and decline 
later. But a failure to decline over time and being persistently elevated should point 
towards the development of an infective process and may increase the chances of 
mortality [64], hence making it a prognostic indicator in burn patients.
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Some of the other notable markers pertaining to burns patients are - Presepsin 
which is the soluble form of cluster of differentiation 14 (CD14), a glycoprotein that 
functions as receptor for endotoxin complexes triggering signal transduction path-
ways implicated in systemic inflammation. In a study conducted on burns patients, 
Presepsin elevation preceded the elevation of CRP and PCT by 1 day as a marker 
of sepsis [65]. Several individual studies have reported the diagnostic accuracy of 
presepsin (sCD14-ST) for sepsis, but the results are inconsistent. Presepsin is an 
effective adjunct biomarker for the diagnosis of sepsis, but is insufficient to detect 
or rule out sepsis when used alone [66]. Single-nucleotide polymorphisms (SNPs) 
which are variations in a nucleotide at a specific chromosome location and has 
been linked to sepsis susceptibility and differences in prognosis in burns patients 
[67]. Gene-expression patterns like the leukocyte transcriptome shifts towards 
increased expression of genes involved in innate immunity and the inflammatory 
response and has been noted in burns patients [68]. But, most of these markers 
are not useful in day to day practice and have been limited to research settings at 
present. Nonetheless, the possibility of these markers making way into the clinical 
domain in the future cannot be ruled out.
7. Acute kidney injury
Conventionally, renal function tests which include serum levels of creatinine, 
urea and assessment of glomerular filtration rate are the methods used to quantify 
renal diseases. But, these conventional methods have a huge drawback. There is an 
unacceptable high time lag between the onset of tissue injury and derangement of 
these biochemical values. This hinders any active reno-protective interventions that 
may be initiated promptly. Moreover, the serum levels of these markers vary widely 
even in healthy individuals as it depends on various physical factors like age, gender, 
muscle mass etc. This has led the medical community to look for alternatives. 
Human neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule 
1 (KIM-1), interleukin-18 (IL-18), cystatin C, clusterin, fatty acid binding protein, 
and osteopontin are the prominent ones that have been studied and NGAL has been 
the most prominent one of the lot.
7.1 Neutrophil gelatinase-associated lipocalin (NGAL)
Neutrophil Gelatinase-associated Lipocalin (NGAL) is a protein that is 
expressed in neutrophils and has a role in innate immune response as well as repair 
and reepithelialisation in the kidney. In patients with acute kidney injury, ischemic 
or nonischemic type, plasma/urine levels of NGAL have been found to be elevated. 
(>50 μg/L)[69]. Both urinary and plasma levels of NGAL were found to increase 
by more than 10-fold within 2–6 hours of cardiac surgery in patients who later 
developed acute kidney injury. Urinary NGAL has been studied more extensively 
in paediatric population and has been found to be useful in detecting kidney injury 
following transplantation, cardiac surgery as well as contrast induced nephropathy 
early [70, 71].
Other markers that are being studied for their utility in kidney injury are 
Interleukin-18, Kidney injury molecule 1 (KIM-1), Cystatin – C, Sodium/Hydrogen 
Exchanger Isoform 3(NHE3) and Liver-type fatty acid binding protein (L-FABP). 
Kidney injury molecule 1 (KIM-1) and Interleukin-18 are found to be elevated in 
case of ischemic Acute Tubular Necrosis [72, 73]. Cystatin-C has been found to 
be better at estimating the GFR than the conventional method using creatinine 
[74]. Sodium/Hydrogen Exchanger Isoform 3(NHE3), which is found in the urine 
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following tubular injury, has been found to be better than fractional excretion of 
sodium in differentiating between pre renal and intrinsic renal causes for renal 
failure [75]. Liver-type fatty acid binding protein (L-FABP) has also shown prom-
ise in animal studies for early detection of AKI and is being adapted as a possible 
biomarker for AKI [76].
8. Traumatic brain injury
8.1 Traumatic brain injury—acute injury
Traumatic brain injury is a major cause of morbidity and mortality across the 
world [77]. The reasons are several, but the lion’s share of the incidents can be 
attributed to the high speed motor vehicle collisions. In addition to that, there 
are other contributing factors like falls as well as injuries due to contact sports. 
The acute injuries can be devastating and even fatal, but a huge number of those 
patients also develop chronic neurological sequelae which can be debilitating [78]. 
Given the complexity of the situation, the understanding of the mechanisms and 
pathophysiology of these chronic conditions are much less understood compared to 
their acute counterparts [79].
Traumatic Brain Injury (TBI) can be classified into acute or chronic based on 
the acuity of the event. Acute traumatic events as a result of MVA (motor vehicle 
accidents), falls or sporting events mostly result in immediate clinical symptoms or 
signs that are often diagnosed with the help of neuroimaging immediately by the 
clinician. A concussion as a result of contact sports or accidents can result in clinical 
features which can range from mild dizziness to complete unconsciousness. But, it 
will exhibit no discernible defects in neuroimaging of the patient [80]. Therefore 
it becomes a clinical diagnosis rather than a radiological diagnosis. Many patients, 
especially sportspersons who are part of contact sports like boxing have exhibited 
persistent symptoms for hours to days to months after the insult [81]. The shear-
ing forces in an acceleration/deceleration injury causes axonal damage which is 
often responsible for the clinical manifestations. The acute event leads to a primary 
insult to the central nervous system which can manifest as cerebral oedema or even 
intracranial haemorrhage. This in turn leads to increase in the intracranial pressure 
which in turn causes cerebral hypoperfusion and resultant tissue hypoxia [82].
Traumatic head injury is not an area which usually requires a biomarker evalu-
ation from the Neurosurgeon’s point of view for the purpose of acute care. Clinical 
decision making is often dependent on neuroimaging, which is a CT scan usually. 
But, recently, the role of biomarkers has become important in the decision making 
process of getting a neuroimaging. This is done with a view of reducing the radia-
tion exposure to patients with mild head injury. These biomarkers are not usually 
present in the circulation and their presence generally indicates a breach of Blood–
brain barrier. Some of the important biomarkers described in the recent literature 
are Glial fibrillary acidic protein (GFAP), calcium binding protein S100B, and 
tau protein [83]. The most important one in the horizon is S100 calcium binding 
protein B (S100B), which is a glial-specific protein which is primarily expressed by 
a subtype of mature astrocytes. It is elevated in neuronal damage which makes it a 
potential marker for CNS insults. In a study done on 512 adult patients with mild 
head injury (GCS 14–15, loss of consciousness and/or amnesia and no additional 
risk factors), the researchers used protein S100B levels as a clinical tool to determine 
whether the patient needed a CT scan [84]. They found that adult patients with 
mild head injury, without additional risk factors and with S100B levels of <0.10 
mcg/L within 3 hours of injury, can safely be discharged from the hospital without 
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neuroimaging. A recent study done in Sweden tries to shed light on the utility of 
biomarkers like total tau, protein S100B and neuron-specific enolase in assessing 
concussion injuries in sports persons [85].
8.2 Traumatic brain injury - chronic Sequelae
Once the primary insult is over, the brain can suffer from secondary injury as a 
result of sequelae from the initial insult. This can occur after days, weeks, months 
or years after the initial event. This results from biochemical cascades that are trig-
gered by the primary event. These secondary events are mediated by free radicals 
and reactive oxygen species that are generated as a result of tissue hypoxia, reperfu-
sion injury and neuroinflammation [86]. The change in membrane permeability 
which results from the initial injury causes increase in the calcium uptake or activa-
tion of NMDA and AMPA receptors by glutamate can cause mitochondrial dysfunc-
tion [87]. Thus the inflammatory response leads to further cellular disruption and 
the vicious cycle continues to damage the nervous homeostasis. These inflammatory 
insults in the nervous system give rise to various inflammatory markers which can 
be detected in the system. These biomarkers have been extensively studied and their 
usefulness in the clinical environment hotly debated. Even though many of these 
markers many of them show enough promise within the confines of the laboratory, 
they are yet to come to the bedside to be used by the clinician in daily practice.
Many animal studies have demonstrated an increase in biochemical markers 
even after a single day after the insult and these can persist even after a month [88]. 
Acrolein, a post-traumatic neurotoxin can be quantified in brain tissue and can be 
elevated depending on the insult. A sustained upregulation has been demonstrated 
after brain injury, which suggests that it is a potential marker for neuronal injury 
and inflammation [89].
Proton Magnetic Resonance Spectroscopy (1H-MRS) is a technique which is 
able to measure the neurochemicals in the nervous system. This helps in detecting 
the neurotransmitters and metabolites, thereby quantifying the markers in various 
clinical conditions. Using this method, animal studies have found that endogenous 
antioxidants glutathione and ascorbic acid may be decreased up to 2 weeks follow-
ing the insult [90]. F2-isoprostane, a lipid peroxidation by-product, has been found 
to be elevated on chronic brain injury or Chronic Traumatic Encephalopathy (CTE) 
which manifests years after the insult(s).
As detected by Proton Magnetic Resonance Spectroscopy (1H-MRS), there 
have been consistent results in detection of the following neurotransmitters in 
children with Autism Spectrum Disorder(ASD). There has been reduced levels of 
N-acetylaspartate (NAA), Creatine and phosphocreatine (Cr + PCr), Glutamine, 
Myo-Inositol and Choline containing compounds in the subcortical areas as well as 
cortical white matter and grey matter in varying degrees in children with ASD [91].
8.3 Neurodegenerative diseases
Neurodegenerative diseases can be extremely debilitating and distressing to not 
only the patient, but also the caregivers. Once diagnosed, the pathophysiological 
mechanisms can seldom be reversed and hence it becomes the source of social, 
financial and economic drain for not only families, but for the governmental health 
machinery itself. The social impact is huge, but the economic impact of these condi-
tions cannot be ignored by any means.
Hence, it becomes imperative that the diagnosis can be made as early as possible 
thereby mitigating the scenario. An earlier diagnosis will help the clinician as well 
as the caregivers to come to a plan for further care of the patient. It is also essential 
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to look at the therapeutic interventions which can arrest or at least slow down the 
progression of the disease. This is where the role of biomarkers come into picture. A 
biomarker can help in diagnosing a particular condition early. Even if the diagnosis 
cannot be confirmed, at least the possibility of the condition can be ascertained and 
hence be prepared against. This is where a biomarker helps in fighting the diseases 
which for all practical purposes, have no definitive curative measures available by 
the bedside.
Biomarkers in neurodegenerative conditions can be classified as fluid and 
radiological markers. Since radiology is an integral and essential part of assess-
ment of the neurological system in modern medicine, many techniques have been 
developed which can detect the presence of markers within the brain tissue which 
can point towards the presence or likelihood of a particular disease condition. On 
the other hand, there are fluid biomarkers that can be detected in the fluid that 
flows all over the brain - the cerebrospinal fluid (CSF). Before we look into those 
markers, it needs to be kept in mind that quite a few markers have gone to the lab in 
the hunt for that perfect biomarker. But, none of them has been successful enough 
to be brought to the bedside for daily clinical practice. Among the many neurode-
generative conditions, Alzheimer’s disease has been the most extensively studied, 
because of its prevalence and impact on the society. But the biomarkers used in 
Alzheimer’s disease do overlap with many other conditions as well due to similari-
ties in pathophysiology.
Biomarkers in neurodegenerative conditions can be detected in blood and cere-
brospinal fluid (CSF) and are clubbed together to be called as fluid markers. The pre-
dominant ones are Amyloid β peptides/oligomers and Tau peptides. Neurofilament 
light chain (NfL), which is found in myelinated axons, is an important marker 
which indicates white matter damage and points towards neurodegeneration [92]. 
Serial NFL sampling in patients at risk of developing Alzheimer’s Disease, can be 
used to predict brain atrophy rates, cognitive impairment and disease progression 
[93]. These can be estimated by assays in blood as well as CSF. The major disadvan-
tage these markers face is the low specificity and that hinders its utility in clinical 
practice. Another set of markers or radiological distinction characteristics can be 
detected in MRI and PET scans and are termed as radiological biomarkers. MRI 
utilises the various imaging modalities available to detect white matter lesions that 
are present in many of the neurodegenerative diseases. These include reduction in 
the volume, thickness, presence of microbleeds, myelin, iron, neuromelanin within 
the brain tissue in specific regions. PET targets various Tau lesions and Amyloid β 
aggregates in various regions within the neuronal system to detect the possibility of 
neurodegeneration. Apart from these, there are genetic biomarkers or specific genes 
that can predict the possibility of a neurodegenerative disease condition (Table 4).
Gene(s) Disease syndrome associated
APP, PSEN1, PSEN2 Familial - Early-onset Alzheimer’s disease
ApoE (ε4 allele), TREM2 AD- Risk factors
MAPT, C9orf72, GRN Behavioural-variant frontotemporal dementia
VCP, TARDBP, SOD1, FUS Amyotrophic Lateral Sclerosis
HTT Huntington’s disease
SNCA, GBA Parkinson’s disease
PRNP Prion Disease
Table 4. 
Genetic biomarkers for neurodegenerative diseases.
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8.3.1 Alzheimer’s disease
It is a proteinopathy which is characterised by accumulation of Tau neurofibril-
lary tangles and extracellular Amyloid β plaques. These can be assessed by radio-
logical methods as well as by looking at the fluid biomarkers. It has a prolonged 
pre-clinical phase where there Tau lesions can be found in the subcortical regions 
even before profound clinical symptoms appear [94]. Similarly amyloid β aggre-
gates are initially found in the neocortical regions and later subcortical and cerebel-
lar regions [95]. Plasma levels of Aβ42 has been found to be decreased compared 
to controls in a study [96]. The National Institute on Ageing and Alzheimer’s 
Association Research Framework has defined AD by its underlying pathologic 
processes that can be documented by post-mortem examination or in vivo by 
biomarkers [97]. The biomarkers are classified into the 3 major groups- β amyloid 
deposition, pathologic tau, and neurodegeneration - AT(N). As and when newer 
biomarkers are discovered, they may be added into these categories. When it comes 
to therapeutics targeted based on these markers, there is still a long way to go to get 
these implemented in clinical practice. This may be due to the lack of direct correla-
tion between the marker load with the clinical deterioration [98] as well as lack of 
specificity [99].
8.3.2 Parkinson’s disease
It is the most common presentation of synucleinopathy. The presentation can 
be similar to other similar conditions like Dementia with Lewy bodies. The typical 
feature can be aggregation of α-synuclein in the form of Lewy bodies which starts in 
the subcortical regions and later spread into the other regions [100]. Apart from the 
mutations in the genes, causality has been attributed to pesticide exposure as well as 
traumatic brain injury [101].
8.3.3 Frontotemporal lobar degeneration
This encompasses a spectrum of disease conditions characterised by vacuola-
tion, gliosis and neuronal loss in the cortical regions of the frontal and temporal 
lobes. Features of Tau protein accumulation, TDP-43 or fused in sarcoma can 
be seen in this condition [102]. Since they share a similar pathophysiology, 
Amyotrophic lateral sclerosis (ALS) and other similar motor neuron diseases are 
considered to be part of the same spectrum.
Huntington’s disease is characterised by progressive neuronal loss and astroglio-
sis in the striatum along with prominent degeneration of the other cortical regions 
[103]. Similar to other disease conditions, there is limited data available to look at 
the therapeutic use of markers in HD also. Plasma levels of IL-8, TNF-α [104], and 
NfL may become useful in the coming years in this regard. A decrease in the uptake 
of phosphodiesterase-10 PET tracer in the strial region may become an important 
marker with regard to therapeutics in HD [105]. Diagnosis of Prion diseases like 
sporadic Creutzfeldt-Jakob disease (sCJD) is done by EEG, MRI or CSF based 
biomarkers with the use of real-time quaking-induced conversion (RT-QuIC) which 
is preferred over 14-3-3 protein detection [106].
Since many of the neurodegenerative conditions present late in clinical practice, 
it is imperative that in order to tackle this menace, the scientific community will 
have to bring forth tools that can detect these early as well us much ahead of the 
phase of clinical presentation, even decades. It is in this regard, the biomarkers have 
a major role to play, whether they are radiological or fluid markers. Genetic markers 
are useful when we are dealing with hereditary conditions or familial variants of 
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neurodegenerative conditions. Confirmation of the diagnosis is essential in deter-
mining the treatment and initiating it at the earliest for the best possible response.
8.4 Newer modalities in the horizon
Even though the field of biomarker evaluation is not very old, it is a fast chang-
ing world and newer techniques are being added to the mix quite often. A recent 
technique is the Multimer Detection System-Oligomeric Aβ, which looks at the 
tendency of plasma proteins to oligomerize [107]. Immune-infrared sensor assay to 
measure blood vessels for the propensity of the amyloid protein to form β-sheets has 
also been tried with some success as a potential biomarker [108]. Measurement of 
locus coeruleus, an early affected region, using special MRI techniques is also being 
explored as a potential target [109].
9. Point of care tests (POCT)
POCT refers to diagnostic evaluation at or near the site of patient care. A POC 
lab is not within the institutional central laboratory, but nearer to the patient care 
setting like ED or ICU. POC testing of biomarkers is increasingly becoming the 
norm at the moment. This has been touted as the next revolutionary step in faster 
healthcare delivery in the Emergency department. But, the challenge lies in trans-
ferring the resultant advantage to improvement in patient care and disposition. The 
benefit demonstrated on paper should be translated to better patient care by the 
bedside. If the results of the POC testing do not alter the course of management of 
the patient, it defeats the whole purpose of POCT.
10. Future of biomarker use in emergency medicine
Biomarkers are being increasingly used in the Emergency departments for faster 
patient disposition. Recently efforts are being undertaken to include an array of 
biomarkers in the triage scoring itself as a method of risk stratification of patients 
presenting to the ED [110]. In this study, the researchers included biomarkers from 
3 distinct biological pathways for risk stratification of general medical patients 
presenting to the ED. The study included biomarkers of inflammation (pro-
adrenomedullin [ProADM]), stress (copeptin) and infection (procalcitonin). They 
used a multi-marker approach to stratify patients and came to a conclusion that all 
the markers strongly predicted the risk of death, ICU admission and high initial 
triage priority, especially ProADM. It is a possibility that these methods may get 
introduced in clinical practice in the not so distant future.
11. Conclusion
Biomarkers are among the best tools in the hand of the clinicians at present. 
Each and every clinical condition has been tagged with a quantifiable biomarker 
which helps in faster clinical diagnosis as well as prognostication. Overall this would 
lead towards better healthcare delivery to the patient. But, the sheer vast numbers 
and volumes of various biomarkers in the research pipeline points towards a glaring 
fact. There is no single marker that can give a complete picture of the patient’s 
clinical condition. There is no ideal biomarker. A scoring system based on multiple 
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markers would give a better picture than a single one. This accuracy always comes 
at a higher cost, which translates to more expensive healthcare delivery. There is 
dire requirement for better clinical validation among the various contenders in each 
disease process A biomarker based evaluation system, though more accurate, may 
not suit each and every healthcare facility, but needs to be tailored based on the 
adaptability and cost effectiveness suited to the society it caters to. Given the vast 
array of biomarker assays, clinicians should keep in mind that these should always 
be used as tools that compliment your clinical decision making process rather than 
replacing the process itself.
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